Omega-3 EPA & DHA: The Complete Science of Fish Oil for Inflammation, Brain Health, and Cardiovascular Protection

Omega-3 fatty acids are long-chain polyunsaturated fats that the human body cannot synthesize from scratch — they must come from diet or supplementation. Of the primary dietary omega-3s, eicosapentaenoic acid (EPA, 20:5 n-3) and docosahexaenoic acid (DHA, 22:6 n-3) are the biologically active forms with direct mechanistic roles in inflammation resolution, cardiovascular regulation, and central nervous system structure. Alpha-linolenic acid (ALA, found in flaxseed and walnuts) is technically an omega-3 but converts to EPA and DHA at less than 10% efficiency in humans — making marine-sourced EPA/DHA supplementation essential for achieving therapeutic tissue concentrations.

The modern Western diet delivers an omega-6:omega-3 ratio of approximately 15:1 to 20:1, dramatically skewed from the evolutionary 4:1 ratio. This imbalance drives chronic low-grade inflammation and is associated with increased risk of cardiovascular disease, depression, cognitive decline, and inflammatory conditions. Restoring EPA and DHA intake is one of the most evidence-backed interventions in nutritional science.

EPA vs DHA: Different Molecules, Different Roles

EPA and DHA are both long-chain omega-3 polyunsaturated fatty acids, but their structural differences produce meaningfully distinct biological functions. Understanding this distinction is critical for matching supplementation strategy to health goals.

Structural Differences

EPA (20:5 n-3) is a 20-carbon chain with 5 double bonds. DHA (22:6 n-3) is a 22-carbon chain with 6 double bonds. The additional length and extra double bond in DHA make it extraordinarily flexible — DHA's U-shaped molecular conformation is uniquely suited to neuronal membranes where fluidity and rapid conformational changes are required for signal transduction. EPA, being shorter, integrates more readily into cell membranes involved in immune signaling and eicosanoid production.

The Eicosanoid Pathway

When membrane phospholipids are cleaved by phospholipase A2 during cellular stress, the released fatty acid determines which eicosanoids are produced. Arachidonic acid (AA, omega-6) generates pro-inflammatory prostaglandins (PGE2), thromboxanes (TXA2), and leukotrienes (LTB4) via cyclooxygenase (COX) and lipoxygenase (LOX) enzymes. EPA competitively inhibits this process by occupying the same enzymatic binding sites, producing 3-series prostaglandins and 5-series leukotrienes that are significantly less pro-inflammatory (often 10–100x less potent) than their AA-derived counterparts.

This competitive inhibition explains why dietary omega-6:omega-3 ratio matters — when AA dominates membrane composition, inflammatory signaling is amplified; when EPA is abundant, it acts as a molecular brake on the COX/LOX cascade.

Resolvin and Protectin Synthesis

Beyond simply blocking inflammation, EPA and DHA are enzymatically converted into specialized pro-resolving mediators (SPMs) — a class of lipid molecules that actively terminate inflammatory responses. EPA generates E-series resolvins (RvE1, RvE2); DHA generates D-series resolvins (RvD1–RvD6), protectins (neuroprotectin D1), and maresins. These SPMs signal via dedicated G-protein-coupled receptors to promote neutrophil apoptosis, macrophage phagocytosis of cellular debris, and restoration of tissue homeostasis. This "pro-resolution" mechanism is distinct from simple anti-inflammation — SPMs switch off the inflammatory program rather than merely suppressing it, without the immunosuppressive side effects of corticosteroids or NSAIDs.

Cardiovascular Evidence: Trials, Mechanisms, and Clinical Translation

Omega-3 fatty acids have one of the richest cardiovascular evidence bases in nutritional science, culminating in several landmark randomized controlled trials and a mechanistic understanding that spans multiple parallel pathways.

REDUCE-IT Trial (2018)

The REDUCE-IT (Reduction of Cardiovascular Events with Icosapentaenoic Acid–Intervention Trial) randomized 8,179 adults with elevated triglycerides and established cardiovascular disease or diabetes to 4g/day of icosapentaenoic acid (pure EPA as ethyl ester, Vascepa) vs. mineral oil placebo. The result was a 25% reduction in the primary composite cardiovascular endpoint and a 30% reduction in cardiovascular death over a median follow-up of 4.9 years. The magnitude of benefit was substantially larger than expected from triglyceride reduction alone, suggesting EPA's membrane-stabilizing and anti-inflammatory properties contributed independently.

REDUCE-IT was the inflection point that drove FDA approval of icosapentaenoic acid for cardiovascular risk reduction and generated significant debate about whether EPA alone or EPA+DHA combinations produce superior outcomes.

JELIS Trial (2007)

The Japan EPA Lipid Intervention Study randomized 18,645 Japanese hypercholesterolemic patients to 1.8g/day EPA (as ethyl ester) added to statin therapy vs. statin alone. Over 4.6 years, EPA supplementation produced a 19% reduction in major coronary events (P=0.011). The absolute event rate was lower in Japan than Western populations (reflecting dietary EPA/DHA intake from fish), making the relative risk reduction especially notable.

Cardiovascular Mechanisms

Multiple parallel mechanisms explain omega-3 cardiovascular benefit:

• Triglyceride reduction: EPA and DHA inhibit hepatic VLDL synthesis and increase lipoprotein lipase activity, reducing fasting triglycerides by 15–30% at 2–4g/day — one of the most potent non-pharmacological triglyceride-lowering interventions available.
• Anti-platelet aggregation: EPA-derived TXA3 is a weak platelet activator compared to AA-derived TXA2, reducing thrombotic risk without the bleeding hazard of aspirin.
• Endothelial function: EPA and DHA increase eNOS (endothelial nitric oxide synthase) expression, improving endothelium-dependent vasodilation and reducing arterial stiffness.
• Anti-arrhythmic: DHA incorporation into cardiomyocyte membranes modulates sodium and calcium channel kinetics, reducing ventricular arrhythmia susceptibility — a mechanism particularly relevant to sudden cardiac death prevention.
• Plaque stabilization: EPA accumulates in atherosclerotic plaque and reduces its lipid content and macrophage infiltration, producing a more stable, less rupture-prone lesion.

Brain Health & Cognition: DHA's Role in Neuronal Architecture

The brain is the most lipid-rich organ in the body (by dry weight), and DHA constitutes approximately 40% of all polyunsaturated fatty acids in brain gray matter. This concentration is not passive — DHA's unique molecular flexibility is structurally essential for neuronal membrane function, synaptogenesis, and neurotransmitter receptor activity.

DHA in Neuronal Membranes

Neurons require membranes that can rapidly change shape during action potential propagation and synaptic vesicle fusion. DHA's six double bonds create a highly flexible, fluid membrane domain that facilitates the conformational changes required by ion channels, G-protein-coupled receptors, and membrane fusion proteins. When DHA is depleted from neuronal membranes (as occurs with age, chronic inflammation, or dietary insufficiency), membrane fluidity decreases, synaptic transmission slows, and neuroplasticity is impaired. DHA is also preferentially incorporated into synaptic phosphatidylserine and phosphatidylethanolamine, which are critical for maintaining membrane asymmetry and lipid raft signaling platforms.

During prenatal and early postnatal development, DHA is actively transferred across the placenta and into breast milk. Low maternal DHA is associated with impaired visual acuity, language development, and IQ in offspring — supporting DHA supplementation during pregnancy and lactation.

Depression Meta-Analyses

The relationship between omega-3 status and depression is biologically plausible: DHA supports serotonin receptor function, and EPA reduces neuroinflammation implicated in depression pathophysiology. A 2013 meta-analysis by Lim et al. (covering 13 RCTs, 1,233 participants) found that EPA-predominant formulations (EPA > 60% of total omega-3) significantly reduced depressive symptoms (standardized mean difference −0.50, 95% CI −0.92 to −0.08), with the effect size comparable to first-line antidepressant medications. Importantly, the meta-analysis found that DHA-only formulations showed no antidepressant effect, implicating EPA's anti-inflammatory mechanisms (rather than membrane incorporation) as the primary driver of mood benefit.

Cognitive Decline Prevention

The MIDAS (Memory Improvement with Docosahexaenoic Acid Study) by Yurko-Mauro et al. (2010) randomized 485 adults with age-related cognitive decline to 900mg/day DHA vs. placebo for 24 weeks. The DHA group showed significantly improved learning and memory function equivalent to reversing approximately 3 years of cognitive aging. Longitudinal epidemiological data consistently show that higher dietary fish intake and higher blood DHA levels are associated with reduced risk of Alzheimer's disease and slower cognitive aging, though the causality of these associations remains under investigation in larger intervention trials.

Anti-Inflammation Mechanisms: From COX/LOX to Specialized Pro-Resolving Mediators

Omega-3s operate across multiple distinct anti-inflammatory mechanisms simultaneously — a mechanistic breadth that distinguishes them from single-target anti-inflammatory drugs.

COX/LOX Pathway Modulation

Cyclooxygenase-1 (COX-1) and COX-2 enzymes convert arachidonic acid (AA) into prostaglandins and thromboxanes that initiate inflammation, pain, fever, and platelet aggregation. EPA competes directly with AA for COX binding, and when EPA is metabolized by COX-2, it produces 3-series prostaglandins (e.g., PGE3) that are 10–100x less inflammatory than AA-derived PGE2. Similarly, EPA-derived 5-series leukotrienes (LTB5) from the LOX pathway have dramatically reduced chemotactic potency compared to AA-derived LTB4, the primary neutrophil attractant in acute inflammation.

Specialized Pro-Resolving Mediators (SPMs)

SPMs represent a paradigm shift in understanding omega-3 anti-inflammatory action — they don't merely block inflammation but actively program its resolution:

• E-series resolvins (RvE1, RvE2) — derived from EPA via aspirin-acetylated COX-2 or cytochrome P450 enzymes. RvE1 acts on ChemR23 and BLT1 receptors to halt neutrophil recruitment and stimulate macrophage clearance of apoptotic cells.
• D-series resolvins (RvD1–RvD6) — derived from DHA, acting on GPR32 and ALX/FPR2 receptors. RvD1 reduces neutrophil infiltration and promotes macrophage phagocytosis in a manner that does not impair immune defense.
• Protectin D1 (neuroprotectin D1 in neural tissue) — DHA-derived, potently neuroprotective; reduces amyloid-beta production and promotes neuronal survival in models of Alzheimer's and ischemic injury.
• Maresins — macrophage-derived DHA metabolites that accelerate tissue regeneration and wound healing while counter-regulating pain sensitization.

Omega-6:Omega-3 Ratio: Why It Matters

EPA and DHA compete with arachidonic acid at every level: membrane incorporation, enzyme binding, and signaling receptor occupation. The ratio of omega-6 to omega-3 in tissue membranes determines which eicosanoid profile predominates. At the evolutionary 4:1 ratio, inflammatory signaling is appropriately calibrated — acute inflammation occurs efficiently and resolves completely. At the 15–20:1 ratio typical of Western diets, chronic low-grade inflammation becomes the metabolic default — contributing to insulin resistance, cardiovascular disease, neuroinflammation, and accelerated aging. Supplementation with 2–4g EPA+DHA daily, combined with reduced linoleic acid (omega-6) intake, can shift the tissue ratio toward a more physiological balance over 4–8 weeks.

Dosing, Forms, and Quality: How to Choose and Use Fish Oil

Not all omega-3 supplements are equivalent. Form, purity, dosing strategy, and timing each influence efficacy and tolerability. Understanding these variables is essential for translating the clinical evidence into practical supplementation.

Triglyceride vs. Ethyl Ester Form

Commercial fish oil is available in two primary molecular forms:

• Triglyceride (TG) form: EPA and DHA are esterified to a glycerol backbone, identical to the natural form in fish. Absorption is approximately 50% higher than ethyl ester form when taken with food. Re-esterified triglyceride (rTG) concentrates are manufactured by removing then reattaching EPA/DHA to glycerol, producing high-concentration (50–90% omega-3) products in the natural TG form — generally considered the premium option.
• Ethyl ester (EE) form: EPA and DHA are bound to ethanol rather than glycerol. Production is less expensive, and concentration is easier — REDUCE-IT and many other trials used EE formulations. EE form has lower baseline absorption but significantly improves when taken with a high-fat meal. The clinical evidence base for EE is robust despite the absorption disadvantage.
• Phospholipid form (krill oil): EPA and DHA naturally bound to phosphatidylcholine. The phospholipid carrier may enhance intestinal absorption and facilitates direct incorporation into cell membrane phospholipids. Krill oil also contains astaxanthin (a potent antioxidant) that protects EPA/DHA from oxidation. Dose per capsule is typically lower than fish oil — require more capsules for equivalent EPA+DHA delivery.

Rancidity and Quality Testing

Oxidized fish oil is not inert — rancid omega-3s may counteract the anti-inflammatory benefits and produce pro-oxidant effects. Fish oil oxidizes rapidly on exposure to air, heat, and light. Quality markers to look for:

• Peroxide value (PV) <5 mEq/kg (GOED standard); ideally <3 mEq/kg
• Anisidine value (AV) <20 (measures secondary oxidation products)
• TOTOX value (2×PV + AV) <26
• Third-party certification: IFOS (International Fish Oil Standards) 5-star rating, NSF International, or USP verification
• Fresh fish oil should smell mildly oceanic — a strong fishy odor indicates oxidation

Optimal Dosing Strategy

Clinical evidence suggests the following dosing framework:

• General health maintenance: 1–2g combined EPA+DHA daily
• Anti-inflammatory / cardiovascular: 2–4g EPA+DHA daily (the range used in REDUCE-IT and JELIS)
• Depression adjunct: 1–2g/day EPA-predominant formulations (>60% EPA)
• Cognitive support: 900mg–2g DHA daily
• Triglyceride reduction: 3–4g EPA+DHA daily (comparable to prescription Lovaza/Vascepa)

Timing: Always take omega-3 supplements with the largest fat-containing meal of the day. Fat in the meal stimulates bile secretion and pancreatic lipase activity, which are required for omega-3 absorption — taking fish oil on an empty stomach reduces absorption by 30–50% and increases the likelihood of GI side effects ("fish burps").

Krill Oil vs. Fish Oil: Practical Considerations

Krill oil provides EPA and DHA in phospholipid form, which may deliver superior brain and cellular membrane incorporation. The phospholipid-bound EPA/DHA also produces fewer GI side effects. However, krill oil is 3–5x more expensive per gram of EPA+DHA than high-quality fish oil, and the clinical trial database is substantially smaller. For individuals who experience GI intolerance to fish oil or who prioritize brain uptake, krill oil is a reasonable premium option. For cardiovascular-focused protocols at therapeutic doses (3–4g/day), fish oil in rTG form offers the best combination of evidence, dose flexibility, and cost-effectiveness.

Key Clinical Evidence